Galcanezumab

Summary

Galcanezumab (CHEMBL3707328) is an approved antibody (ATC N02CD02); indicated across 3 conditions including migraine disorder and osteoarthritis, knee.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: N02CD02
• Indications: 3 conditions
• Clinical trials: 34

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707328
Name	Galcanezumab
Type	Antibody
Max phase	4
ATC	N02CD02

Also known as: Emgality, Galcanezumab, Galcanezumab gnlm, Galcanezumab-gnlm, LY-2951742, LY2951742, GALCANEZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
migraine disorder	4	MONDO:0005277	MONDO:0005277
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 34.

Phase distribution

Phase	Trials
PHASE3	12
PHASE4	6
PHASE1	6
Not specified	5
PHASE2	4
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04158752	PHASE4	COMPLETED	Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
NCT04294147	PHASE4	COMPLETED	A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
NCT05127486	PHASE4	COMPLETED	A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
NCT05284019	PHASE4	TERMINATED	Real World Effectiveness of Eptinezumab in Participants With Migraine
NCT05492695	PHASE4	TERMINATED	Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
NCT06901518	PHASE4	COMPLETED	The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
NCT03432286	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT04616326	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT02397473	PHASE3	COMPLETED	A Study Of Galcanezumab In Participants With Episodic Cluster Headache
NCT02438826	PHASE3	COMPLETED	A Study of Galcanezumab in Participants With Chronic Cluster Headache
NCT02614183	PHASE3	COMPLETED	Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
NCT02614196	PHASE3	COMPLETED	Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study
NCT02614261	PHASE3	COMPLETED	Evaluation of Galcanezumab in the Prevention of Chronic Migraine
NCT02614287	PHASE3	COMPLETED	A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura
NCT02797951	PHASE3	COMPLETED	A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
NCT02959190	PHASE3	COMPLETED	A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
NCT03559257	PHASE3	COMPLETED	A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
NCT03963232	PHASE3	COMPLETED	A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
NCT01625988	PHASE2	COMPLETED	A Study of LY2951742 in Participants With Migraine
NCT02163993	PHASE2	COMPLETED	A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
NCT02192190	PHASE2	TERMINATED	A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
NCT02959177	PHASE2	COMPLETED	A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
NCT01337596	PHASE1	COMPLETED	A Study of LY2951742 in Healthy Volunteers
NCT02104765	PHASE1	COMPLETED	A Study of LY2951742 in Healthy Japanese and Caucasian Participants
NCT02576951	PHASE1	COMPLETED	A Study of Galcanezumab in Healthy Participants
NCT02836613	PHASE1	COMPLETED	A Study of Galcanezumab in Healthy Participants.
NCT04085289	PHASE1	COMPLETED	A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants
NCT04179474	PHASE1	COMPLETED	Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
NCT07323927	EARLY_PHASE1	RECRUITING	Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer’s Disease
NCT04628429	Not specified	RECRUITING	CGRP Inhibition, Autonomic Function, and Migraine
NCT06085144	Not specified	RECRUITING	Emgality for Migraine in Breastmilk
NCT06212661	Not specified	ENROLLING_BY_INVITATION	Migraine Medication Effects on Urinary Symptoms
NCT04803513	Not specified	UNKNOWN	Observational Study on the Efficacy, Safety, and Tolerability of GAlcanezumab in Real Life Migraine Patients in ITaly
NCT05281770	Not specified	UNKNOWN	Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).